Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-22
2006-08-22
Pak, Michael (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000
Reexamination Certificate
active
07094752
ABSTRACT:
Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.
REFERENCES:
patent: 5519120 (1996-05-01), Dano et al.
patent: 5656726 (1997-08-01), Rosenberg et al.
Goodson, et al., “High-affinity urokinase receptor antagonists identified with bacteriophage peptide display”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 7129-7133, Jul. 1994.
Ploug et al., “Structure-function relationships in the receptor for urokinase-type plasminogen activator”—“Comparison to other members of the Ly-6 family and snake venom {acute over (α)}-neurotoxins”, FEBS Letters 349 (1994) 163-168.
Wei, et al., “Identification of the Urokinase Receptor as an Adhesion Receptor for Vitronectin”, The Journal of Biological Chemistry, vol. 269, No. 51, Issue of Dec. 23, pp. 32380-32388, 1994.
Doyle et al., (1996) Fibrinolysis 10:21.
Bowie et al., (1990) Science 247: 1307-1310.
Waltz, et al., “Reversible cellular adhesion to vitronection linked to urokinase receptor occupancy”, J Biol Chem, May 20, 1994, 269 (20), p14746-50.
Chapman Harold A.
Doyle Michael V.
Rosenberg Steven
Austin James E.
Brigham and Women's Hospital Harvard Medical School
Chiron Corporation
Harbin Alisa A.
Pak Michael
LandOfFree
Peptide ligands of the urokinase receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide ligands of the urokinase receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide ligands of the urokinase receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3646113